20 results about "Bacteremia" patented technology

The present application belongs to the field of microbial technology, and particularly relates to a bacteriophage preparation for controlling foodborne enterobacter and application thereof, wherein the bacteriophage preparation comprises any one or several of bacteriophage PhiEAS1, bacteriophage PhiEHO11, bacteriophage PhiEHO14 and bacteriophage PhiECL22. The four bacteriophages provided by the present application can be used alone or combined into a bacteriophage cocktail, and the influence of the bacteriophage preparation on enterobacter in different ecologies and environments is explored through bacteriophage cocktail therapy. The results show that the bacteriophage preparation exhibits significant bacteriostatic activity on various food substrates contaminated by Enterobacter hormaechei, such as lettuce, pork, milk, cherry tomato and the like; in an animal model, intraperitoneal injection of the bacteriophage preparation can effectively prevent and treat bacteremia caused by Enterobacter hormaechei, and shows potential as an anti-Enterobacter hormaechei biological control agent.

To provide a type C natriuretic peptide and a method for treating acute lung injury. [Solution] This disclosure relates to the treatment of lung, liver, and / or kidney disorders by administering therapeutically effective doses of (ultra)long-acting C-type natriuretic peptide (CNP), CNP derivatives, (ultra)long-acting CNP derivatives, or (ultra)long-acting CNP receptor (NPRB) agonists to subjects in need. This disclosure also relates to the treatment of non-cardiovascular causes of hypoxia, elevated inflammatory cell levels in the lungs, pulmonary edema, sepsis, bacteremia, fibrosis in general, and / or interstitial lung disease using these.

A method for assessing bacteremia includes the following steps. A blood analysis database is provided. A model establishing step is performed, wherein a plurality of reference cell population data, a plurality of reference complete blood counting data and a plurality of reference white blood cell differential counting data of the blood analysis database are trained to achieve a convergence by a machine learning algorithm model so as to obtain a bacteremia assessing classifier. A blood analysis data of a subject is provided, wherein the blood analysis data includes a cell population data, a complete blood counting data and a white blood cell differential counting data. An assessing step is performed, wherein the blood analysis data is analyzed by the bacteremia assessing classifier so as to obtain an assessing result of bacteremia of the subject.

Compositions and methods are provided for treating bacterial infections, including those that are challenging to treat by conventional medications, such as hospital acquired bacterial pneumonia (HABP), ventilator associated bacterial pneumonia (VABP), and bacteremia, caused by carbapenem-resistant bacteria such as Acinetobacter baumannii and Pseudomonas aeruginosa.

The present invention relates to aqueous ticagrelor solutions provided for intravenous administration for use in the treatment of a Gram-positive bacterial infection in the blood stream of a patient in need thereof. The invention is advantageous to further improve the effectiveness of bacteremia treatments, especially for MSSA and MRSA bacteremia and bacteremia-associated thrombocytopenia.

A diagnostic kit and method for detecting urinary tract infections (UTIs) and bacteremia using a drinking water test in low-resource settings is provided. The kit includes a first bag containing a first culture medium capable of detecting Gram-negative and coliform bacteria through colorimetric and fluorescence indicators, and a second bag containing a second culture medium capable of detecting Gram-positive bacteria through colorimetric indicators. A method of using the kit involves inoculating a sample into each bag, incubating the bags, and observing for color changes and fluorescence to indicate bacterial presence. The kit enables rapid, cost-effective detection of bacterial pathogens in urine and blood samples without specialized laboratory equipment, facilitating early diagnosis and treatment in resource-limited environments.

The invention provides enterococcus faecalis bacteriophage vBEfaS-1017 and application thereof, the enterococcus faecalis bacteriophage vBEfaS-1017 is preserved in China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC NO.46182, and the preservation time is September 6, 2024. The bacteriophage vBEfaS-1017 is high in specificity, short in incubation period and ultrahigh in stability, and has activity under the conditions of extreme pH, high temperature and ultraviolet radiation; by evaluating the in-vitro bactericidal efficacy of the bacteriophage vBEfaS-1017, it is determined that the bacteriophage vBEfaS-1017 can effectively remove a biological membrane formed by host bacteria Ef 10-17, the removal rate is as high as 90%, and the bacteriophage vBEfaS-1017 is expected to become a scavenger for solving the biological membrane. Further experiments prove that the bacteriophage vBEfaS-1017 has in-vivo and in-vitro safety. Through combined use of the bacteriophage and different antibiotics, it is found that combined use of the bacteriophage vBEfaS-1017 and the antibiotic levofloxacin can effectively treat bacteremia of mice, the treatment time after infection can be prolonged by using the bacteriophage in advance, and the bacteriophage has a good application prospect in the aspect of preventing and treating enterococcus faecalis.

The invention provides a pseudomonas aeruginosa bacteriophage and application thereof. The pseudomonas aeruginosa bacteriophage is a bacteriophage phi PA1019, is screened from sewage and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC NO.46181, and the preservation time is September 6, 2024. Furthermore, a homologous recombination technology is utilized to modify the genome of the bacteriophage phi PA1019, and the PslG gene is introduced into the bacteriophage phi PA1019 to obtain the bacteriophage phi PA1019-PslG. The bacteriophage PhiPA1019 and the bacteriophage PhiPA1019-PslG disclosed by the invention both show extremely wide lysis activity and relatively high pH (Potential of Hydrogen) and temperature tolerance. The determination shows that the introduction of the PslG gene obviously enhances the ability of the bacteriophage in the aspects of inhibiting the growth and attachment of the biofilm and removing the biofilm; meanwhile, the treatment effect of the phage on bacteremia of mice is also researched, and the phage phi PA10-19-PslG is higher in cracking speed and stronger in capability on pseudomonas aeruginosa.

The present application belongs to the field of medicine and health, and relates to the use of lipoteichoic acid (LTA) and / or lipopolysaccharide (LPS) positive extracellular vesicles in plasma in the detection of bacterial inflammation and / or bacteremia. Specifically, the present application provides an in vitro method for detecting bacterial inflammation and / or bacteremia, comprising the following steps: providing a sample to be tested from a subject; isolating extracellular vesicles from the sample to be tested; detecting the level of LPS positive extracellular vesicles (LPS + EVs) and / or the level of LTA positive extracellular vesicles (LTA + EVs); if the levels of LPS + EVs and / or LTA + EVs increase, it indicates that the subject has bacterial inflammation and / or bacteremia.

The invention discloses a method and a kit for rapidly separating and identifying bacteria in blood of a bacteremia patient, belongs to the technical field of bacteria detection, and aims to solve the problems of low separation efficiency, long time consumption and poor specificity in the existing bacteria separation and enrichment technology. Magnetic particles with inert material coatings are prepared aiming at G-bacteria and G + bacteria in blood of a bacteremia patient, the G-bacteria and the G + bacteria are captured by utilizing the specificity of the magnetic particles, then separation or enrichment culture is carried out on a compound of the magnetic particles and the bacteria after erythrocyte splitting decomposition and centrifugation are carried out to remove impurities, and the compound of the magnetic particles and the bacteria is obtained. Therefore, efficient sorting and enrichment of bacteria in the blood sample of the bacteremia patient are realized. The inert coating on the surface of the magnetic particle reduces the steps of non-specific adsorption, specific binding of the antibody to bacteria and splitting decomposition of red blood cells, so that impurity interference is remarkably reduced; the treatment time is obviously shortened, and the enrichment efficiency is enhanced.

Hematological parameters, such as monocyte distribution width (MOW) and neutrophil to lymphocyte ratio (NLR) may be used for bacteremia screening. Such screening may be performed using a transducer module which comprises an interrogation zone, an illumination source configured to illuminate the blood sample in the interrogation zone, and at least one light sensor configured to detect illumination from cells from a blood sample in the interrogation zone. With such a transducer module, a screening method may be performed which comprises presenting the blood sample to the transducer module, delivering a hydrodynamically focused stream of the blood sample to the interrogation zone of the transducer module, determining one or more white blood cell population parameters for the blood sample based on measurements from the transducer module, and screening the blood sample for bacteremia using a data processing module.

The invention discloses a copper-iron nanocrystalline material, a preparation method thereof and application of the copper-iron nanocrystalline material in treatment of bacteremia. In the material, the molar ratio of copper to iron is 8: 2, CuO and Fe3O4 form a bicrystal structure, and the surface of the material is modified with a stabilizer containing peroxide groups. By accurately regulating and controlling the metal proportion, it is found for the first time that when the ratio of Cu to Fe is 8: 2, the membrane damage capacity of Cu < 2 + > and the Fenton catalytic activity of Fe < 2 + > / Fe < 3 + > generate a remarkable synergistic interaction effect. An antibacterial mechanism shows that the material is adsorbed on the surfaces of bacteria with negative electricity through electrostatic interaction, the integrity of cell membranes is damaged, and intracellular substances are leaked; the peroxy group on the surface can be used as an endogenous H2O2 source to generate a large amount of hydroxyl radicals under the catalysis of Fe < 2 + > to trigger oxidative stress damage in bacteria, so that efficient killing of methicillin-resistant staphylococcus aureus and other drug-resistant bacteria is realized. In-vivo and in-vitro experiments prove that the material has excellent safety performance, can be used as a biomedical material for treating bacteremia, pneumonia and other infectious diseases caused by MRSA, and provides a new choice for solving the problem of MRSA drug resistance.

This invention relates to a Klebsiella pneumoniae mRNA molecule and its application in mRNA vaccines. This invention constructs multiple molecules encoding Klebsiella pneumoniae (… Klebsiella pneumoniae The mRNA of the antigen was extracted and its molecular sequence was optimized to ensure efficient antigen translation. The mRNA sequence is shown in any one of SEQ ID NO. 9-12. A Klebsiella pneumoniae mRNA vaccine was constructed based on a liposome nanoparticle delivery system. The mRNA vaccine can mediate a highly efficient adaptive immune response, effectively induce the activation of the Th17 / Tc17 axis in the lungs and spleen, which is beneficial to the mucosal defense and cell bactericidal mechanism of Klebsiella pneumoniae. It can establish a resident T cell memory bank in the respiratory tract, support long-term and highly effective protection, significantly reduce the risk of colonization and bacteremia, and inhibit the pro-inflammatory cascade. It also shows broad-spectrum and highly effective protection in multiple serotypes of Klebsiella pneumoniae.

The invention discloses an application of host-derived aFRK mRNA in preparation of drugs for resisting bacteremia caused by drug-resistant staphylococcus aureus. MRNA of mouse-derived FRK activated mutant protein aFRK is synthesized in vitro and is introduced into a host cell through a lipid nanoparticle (LNP) delivery system, and the host-derived aFRK mRNA can be used for preparing drugs for resisting bacteremia caused by drug-resistant staphylococcus aureus. The macrophage can obviously enhance the killing ability of the macrophage on intracellular drug-resistant staphylococcus aureus, listeria monocytogenes and salmonella, so that infectious bacteria are effectively removed, bacteremia symptoms are improved, the survival rate is increased, and the macrophage has important clinical application value.

This invention relates to the field of pharmaceutical synthesis technology, specifically disclosing a 1,3-diamino-7H-pyrrolo[3,2-f]quinazoline derivative and its general structural formula; it also discloses the preparation method and application of this derivative. This 1,3-diamino-7H-pyrrolo[3,2-f]quinazoline derivative exhibits good inhibitory and bactericidal activity against methicillin-resistant Staphylococcus aureus (MRSA) and can be used to prevent and treat diseases caused by MRSA infection. Preferably, these diseases include, but are not limited to, pneumonia, urinary tract infections, bacteremia, sepsis, and suppurative arthritis caused by MRSA in humans and animals. The beneficial effects of this invention are: the 1,3-diamino-7H-pyrrolo[3,2-f]quinazoline derivative of this invention is obtained through a four-step reaction, the preparation method is simple, and the reaction conditions are mild; it has good inhibitory and bactericidal activity against MRSA and can be used to prevent and treat diseases caused by MRSA infection.

The present invention relates to providing an aqueous ticagrelor solution for intravenous administration for use in the treatment of Gram-positive bacterial infections in the bloodstream of a patient in need thereof. The pharmaceutical composition is beneficial to further improving the effectiveness of bacteremia treatment, especially the effectiveness of MSSA and MRSA bacteremia and thrombocytopenia related to bacteremia.

The invention discloses a medical pus suction device, and relates to the technical field of medical instruments, the medical pus suction device comprises a pus suction assembly and a negative pressure generation assembly, the negative pressure generation assembly is connected with a pus storage assembly, the pus storage assembly is connected with the pus suction assembly, the pus suction assembly comprises a pus suction head and an incision part, and the incision part is arranged on the pus suction head. According to the medical pus suction device, the pus suction head can rapidly and aseptically cut the abscess surface and efficiently suck pus, the pus suction time is greatly shortened, the operation process is simplified, and the treatment efficiency is improved. And the negative pressure can be gradually and accurately adjusted through negative pressure generation, so that the device adapts to different patients and abscess conditions, and the risk of injury to tissues is reduced. The device is suitable for sucking nidus pus of patients with furuncle, carbuncle and sepsis, different nidus sizes can cope with different sizes of pus storage assemblies, the treatment efficiency is improved, and bacteremia and sepsis are reduced from the source.

The invention relates to the technical field of medical instruments and microbiological detection, in particular to a blood culture bottle for enriching bacteria, which comprises a bottle body, a bottle cap, a culture medium, a magnetic bead and an anti-interference component, the bottle cap is detachably connected with the bottle body; the culture medium is a liquid culture medium, is positioned in the bottle body and is used for providing necessary nutritional ingredients for the growth of a biological material; the magnetic beads are magnetic particles, are arranged in the culture medium and are used for adsorbing and separating target strains; and the anti-interference assembly is arranged in the culture medium and is used for separating and adsorbing impurities in the culture medium. According to the method, negative charge components (such as lipopolysaccharide and teichoic acid) on the surfaces of bacteria are actively and directionally captured in the culture process through the electrostatic adsorption characteristic of the cationic magnetic beads, and an enrichment path independent of natural proliferation of the bacteria is constructed, so that the detection efficiency of bacteremia is improved, and the capturing efficiency of low-load bacteria in a complex sample is remarkably improved.

The application provides an antibody or fragment thereof binding to Staphylococcus aureus alpha-hemolysin, a composition containing the antibody or fragment thereof binding to Staphylococcus aureus alpha-hemolysin, and the composition is preferably an aqueous injection preparation. The antibody of the application is screened by the strategy of attenuated immunization and virulent screening of alpha-hemolysin, has high affinity to alpha-hemolysin, can effectively block the hemolytic effect of alpha-hemolysin, and is proved to have significant protective or therapeutic effect in alpha-hemolysin sepsis model, MRSA bacteremia model and MRSA lung infection model. On the basis of the antibody or fragment thereof binding to Staphylococcus aureus alpha-hemolysin, the antibody stable preparation provided by further component selection and concentration optimization improves the freeze-thaw stability, oscillation stability and light stability of the antibody, and prolongs the shelf life of the antibody preparation, especially the aqueous injection.

The invention relates to phenylene diamine derivatives with certain pharmacological properties resulting from enhancement of epithelial barrier function and / or blocking bacterial translocation through the epithelial barrier. The compounds find use in the treatment of various conditions, including conditions involving translocation of pathogens from the gastrointestinal tract into underlying tissues and vasculature, for example febrile neutropenia, intestinal tissue inflammation, bacteremia and sepsis.